As IFN-free DAAs effectively lead to viral eradication, we might use IFN-free DAAs, if we are careful, in patients who are suspected to be at higher HCC risk, such as those with advanced fibrosis, or past history of HCC. The gene discussed is IFNA1; the disease is hepatocellular carcinoma.